Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial
2019 ◽
Vol 21
(10)
◽
pp. 2327-2332
◽
2015 ◽
Vol 9
(4)
◽
pp. 271-276
◽
2016 ◽
Vol 18
(4)
◽
pp. 366-374
◽
2017 ◽
Vol 9
(1)
◽
pp. 119-126
◽
2018 ◽
Vol 103
(6)
◽
pp. 2291-2301
◽
Keyword(s):